Ekiz Kimya Sanayi ve Ticaret AS (EKIZ) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Ekiz Kimya Sanayi ve Ticaret AS stock TRY 5.31, price TRY 36.40, that is 85.4% below the price, quality 54 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 5.66 TRY – 155.30 TRY · fair‑value band 3.72 TRY – 6.90 TRY · the 36.40 TRY price screens above the 5.31 TRY fair value. As of Nov 4, 2026.
Follow Ekiz Kimya Sanayi ve Ticaret AS in your weekly email
Every Wednesday you see whether Ekiz Kimya Sanayi ve Ticaret AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ekiz Kimya Sanayi ve Ticaret Anonim Sirketi provides olive oil products in Turkey. The company offers extra virgin, natural first, organic extra virgin, refined, and riviera olive oil products. It sells its products under the Weighing, Belluti, Healthy You, Dona Elena, and Ekiz Chemistry brand names.
Show moreShow less
The company was formerly known as Ekiz Yag ve Sabun Sanayii A.S. and changed its name to Ekiz Kimya Sanayi ve Ticaret A.S. in September 2014. Ekiz Kimya Sanayi ve Ticaret Anonim Sirketi was founded in 1946 and is headquartered in Izmir, Turkey.
Stock analysis
Ekiz Kimya Sanayi ve Ticaret AS (EKIZ) currently trades at 36.40 TRY, while our model-based Fair Value estimate is 5.31 TRY, 85% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 5.68 TRY per share, and 0 of the 7 models we run sit above the 36.40 TRY price.
Bear case: the Asset-Based group reads lowest at 0.6700 TRY, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 3.72 TRY (bear) to 6.90 TRY (bull), the price of 36.40 TRY sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Consumer Defensive sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ekiz Kimya Sanayi ve Ticaret AS reported revenue of 58.0M TRY in FY2019 versus 11.5M TRY in FY2015, a compound +49.9%/yr. Reported net income was 3.1M TRY in FY2019.
Key figures
Market cap 338M TRY (≈ $6.7M) Micro · P/S ratio 1.25 · EPS (TTM) −30.46 TRY · Net margin 5.4% · Return on equity −16.5% · Return on assets (EBIT) −3.6% (5-year average) · Operating margin −5.5% · Revenue growth (YoY) −61.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).
What moves the price
The share trades about 77% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at −85%, EKIZ screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (0.6700 TRY to 7.02 TRY). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear3.72 TRYFair Value 5.31 TRYBull6.90 TRY
Price 36.40 TRY · Downside -85.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+32.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+71.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.6%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.9%
’09
’10
’11
’12
’13
’14
’15
’16
’17
’18
’19
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.0% (2014) → −3.6% (2019)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
Compare Ekiz Kimya Sanayi ve Ticaret AS with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−85.4% · Bottom 25%
Profitability
Return on assets6.7% · Above median
Net margin (12 months)−22.1% · Bottom 25%
Operating margin (12 months)−5.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−61.9% · Bottom 25%
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/B36.40× · Priciest 25%
P/S (12 months)1.25× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 36
FUTURE (revenue growth)0· sector 20
PAST (return on equity)0· sector 31
HEALTH (low debt)70· sector 98
DIVIDEND (yield)0· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ekiz Kimya Sanayi ve Ticaret AS Fair Value". https://www.fairvalue-calculator.com/stock/EKIZ
Frequently asked questions
Is Ekiz Kimya Sanayi ve Ticaret AS (EKIZ) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 5.31 TRY versus a price of 36.40 TRY, about 85% lower (overvalued).
What is the fair value of EKIZ?
Our model-based fair value for Ekiz Kimya Sanayi ve Ticaret AS is 5.31 TRY (as of Nov 4, 2026), built from audited fundamentals. The current price: 36.40 TRY.
What is the quality score of EKIZ?
Ekiz Kimya Sanayi ve Ticaret AS has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
Our model-based price target is the fair value of 5.31 TRY (as of Nov 4, 2026) from 7 valuation models. Cautious scenario 3.72 TRY, optimistic scenario 6.90 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Ekiz Kimya Sanayi ve Ticaret AS stock forecast for 2026?
Our models put fair value at 5.31 TRY, about 85% lower versus a price of 36.40 TRY (overvalued). Cautious scenario 3.72 TRY, optimistic scenario 6.90 TRY. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ekiz Kimya Sanayi ve Ticaret AS it is 5.31 TRY per share (as of Nov 4, 2026), against a price of 36.40 TRY. It is the blended result of 7 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Ekiz Kimya Sanayi ve Ticaret AS stock overvalued or undervalued in 2026?
As of Nov 4, 2026, EKIZ trades above its calculated fair value: price 36.40 TRY, fair value 5.31 TRY, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EKIZ?
No. The price is what the market pays today (36.40 TRY); the fair value is what the company's own numbers justify (5.31 TRY). For Ekiz Kimya Sanayi ve Ticaret AS the two are 31.09 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Ekiz Kimya Sanayi ve Ticaret AS worth?
The market values Ekiz Kimya Sanayi ve Ticaret AS at about 338M TRY (market capitalisation, as of Nov 4, 2026). Per share that is 36.40 TRY; our models calculate a fair value of 5.31 TRY per share.
What do the bullish and bearish scenarios say about EKIZ?
Our models span a range for Ekiz Kimya Sanayi ve Ticaret AS: cautious scenario 3.72 TRY, base 5.31 TRY, optimistic 6.90 TRY per share (as of Nov 4, 2026, price 36.40 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
Balance-sheet figures for Ekiz Kimya Sanayi ve Ticaret AS (as of Nov 4, 2026): return on equity −16.5%, debt of 0.61 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is EKIZ from its 52-week high?
Ekiz Kimya Sanayi ve Ticaret AS trades at 36.40 TRY, about 77% below its 52-week high of 155.30 TRY and 12% above the low of 32.54 TRY (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 5.31 TRY is for.
Which stocks are comparable to Ekiz Kimya Sanayi ve Ticaret AS?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ekiz Kimya Sanayi ve Ticaret AS stock attractive at the current price?
The data as of Nov 4, 2026: price 36.40 TRY, calculated fair value 5.31 TRY (−85%), Quality Score 54/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EKIZ calculated?
We run Ekiz Kimya Sanayi ve Ticaret AS through 7 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 5.31 TRY builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Ekiz Kimya Sanayi ve Ticaret AS itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
The closing price on Nov 6, 2026 was 36.40 TRY. Our model-based fair value is 5.31 TRY, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ekiz Kimya Sanayi ve Ticaret AS right now?
The price sits above even our optimistic bull case (6.90 TRY). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (3.72 TRY to 6.90 TRY) leaves room in how you read the outcome.
Key figures of Ekiz Kimya Sanayi ve Ticaret AS
How large is the market capitalisation of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
The market capitalisation of Ekiz Kimya Sanayi ve Ticaret AS is 338M TRY (≈ $6.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
The price-to-sales ratio of Ekiz Kimya Sanayi ve Ticaret AS is 1.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
Earnings per share at Ekiz Kimya Sanayi ve Ticaret AS are −30.46 TRY. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
The net margin of Ekiz Kimya Sanayi ve Ticaret AS is 5.4% (fiscal year 2019). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
The return on equity (ROE) of Ekiz Kimya Sanayi ve Ticaret AS is −16.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
On an EBIT basis the return on assets of Ekiz Kimya Sanayi ve Ticaret AS is −3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
The operating margin of Ekiz Kimya Sanayi ve Ticaret AS is −5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
Revenue at Ekiz Kimya Sanayi ve Ticaret AS is growing −61.9% versus a year earlier (3y avg +71.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)?
Earnings per share at Ekiz Kimya Sanayi ve Ticaret AS are growing −98.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Ekiz Kimya Sanayi ve Ticaret AS in the live analysis
One click puts Ekiz Kimya Sanayi ve Ticaret AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
